Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.75 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | KIF11 | P52732 | 1/20 | 0.53 |
| ▸ | GUSB | P08236 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398149 | 0.85 | KIF11 (0.71) | HTTUSP2KIF11GUSBMAPK1 | |
| SCHEMBL13789190 | 0.84 | USP2 (0.79) | USP2HSD17B10ALDH1A1TDP1POLB | |
| SCHEMBL19732923 | 0.84 | USP2 (0.79) | USP2HSD17B10ALDH1A1TDP1POLB | |
| SCHEMBL19732955 | 0.84 | USP2 (0.79) | USP2HSD17B10ALDH1A1TDP1POLB | |
| SCHEMBL14413255 | 0.84 | PKM (0.68) | HTTUSP2KIF11GUSBMAPK1 | |
| SCHEMBL19732936 | 0.84 | PKM (0.68) | HTTUSP2KIF11GUSBMAPK1 | |
| SCHEMBL8328481 | 0.84 | USP2 (0.58) | HTTUSP2KIF11GUSBMAPK1 | |
| SCHEMBL5351765 | 0.84 | KIF11 (0.77) | HTTKIF11MAPK1PKMHSD17B10 | |
| SCHEMBL6348279 | 0.83 | HTT (0.57) | HTTUSP2KIF11MAPK1ALDH1A1 | |
| SCHEMBL10113452 | 0.83 | HTT (0.66) | HTTKIF11GUSBMAPK1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855716-B2 | Dihydropyrimidine compounds and compositions containing the same | AJINOMOTO CO., INC. (JP) | 2005-02-15 | — | — | US | disclosed |
| US-20020143023-A1 | Dihydropyrimidine compounds and compositions containing the same | AJINOMOTO CO. INC (JP) | 2002-10-03 | — | — | US | disclosed |
| EP-1193259-A1 | DIHYDROPYRIMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143023-A1 | Dihydropyrimidine compounds and compositions containing the same | CACNA1B, CACNA1D, CACNA1G | HTT 1326/4885USP2 4782/4885KIF11 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.